What's new

China medical industry

Baby gets new heart in Wuhan
By LIU KUN,LI LEI | China Daily | Updated: 2019-09-21 04:50
f_art.gif
w_art.gif
in_art.gif
more_art.gif


5d855a3ca310cf3e979d4290.png
Asia's youngest and lightest heart recipient, identified as Ruirui, is held by her mother about three months after she received a transplanted heart in Wuhan, Hubei province. [Photo/for China Daily by Liu Kunwei]

Organ transplants involving infants are always considered challenging, given their stage of development and the severe shortage of matching donors, doctors say.

But a hospital in Wuhan, Hubei province, has advanced the boundaries of medicine by announcing on Thursday they had successfully transplanted the heart of a four-year-old donor into the body of a 66-day-old girl, the youngest such case known in Asia.

The previous infant heart transplant record for Asia, also performed at Wuhan Union Hospital of China, involved a 113-day-old boy who weighed 4.25 kilograms, in 2014.

In the latest case, the infant girl, who was identified as Ruirui to protect her privacy, weighed only 3 kg at the time of the transplant in June — the lightest known heart recipient in Asia.

The operation put surgeons to the test because the procedure involved a challenging mismatch — the diameter of donor's aorta was roughly twice the size of the recipient's, according to Dong Nianguo, who led the surgical team.

"We also faced many challenges in the wake of the surgery," he said.

To facilitate the process, Dong said they had used surgical thread that would dissolve to suture the blood vessels. As the thread was absorbed by the body over time, it would leave room for the organ's growth. They also decided to close her chest little by little so that the oversized heart would gradually fit into recipient's body.

Doctors said that Ruirui, the recipient, is free of postoperative infection risks and is able to breathe without assistance following three months of intensive care.

Ruirui, from Shandong province, is still under close observation in the hospital's intensive care unit.

Her donor was a four-year-old boy who died after falling from a high-rise building in Guangzhou, Guangdong province, about a week before the transplant surgery. His parents agreed to donate his organs in the hope that their son, identified as Tongtong, would continue to live in another way, hospital officials said.

Ruirui's mother, who gave her name as Lin to preserve her privacy, said the girl is her third daughter. The other two are 9 and 11.

When Lin was five months pregnant, a test showed the fetus had aortic stenosis, a cardiac condition in which the aortic valve can fail to open completely. She gave birth in April, though had been cautioned during pregnancy that the baby might need surgery after birth.

One month later, Ruirui was diagnosed with a congenital heart defect. Her cardiac chambers had become bloated, swelling her heart to almost the size of a grown man's and causing breathing difficulties as the swelling organ pressed on her windpipes.

Her situation worsened over the next 10 days, and doctors said a transplant was the only option for her to survive.

Before the surgery, the mother talked to the family of the infant boy who had a successful heart transplant in 2014. "I was greatly inspired by his success story," Lin said, adding that they spoke for more than two hours on the phone when they first talked.
 
.
Chinese blood pump to be tested in US
By WANG XIAOYU | China Daily | Updated: 2019-09-24 02:51
f_art.gif
w_art.gif
in_art.gif
more_art.gif


5d8983b8a310cf3e979da7eb.jpeg
A blood pump developed in China is helping critical heart failure patients live longer lives. PROVIDED TO CHINA DAILY

A blood pump that deploys magnetic levitation technology to better support heart function has been developed by a medical device company in Suzhou, Jiangsu province and will begin clinical trials in the United States next year, according to researchers.

The lemon-sized machine, also known as a left ventricular assist device, is implanted in a patient with a critical heart condition and assists in pumping blood.

It has been used in at least nine trial surgeries led by experts from Beijing's Fuwai Hospital, affiliated with the Chinese Academy of Medical Sciences.

He Xin, a patient who received the device in China, told China Central Television in June that he is now able to climb stairs and walk for hundreds of meters. In the past, he had to take long breaks after walking short distances.

The domestically developed device holds the potential to benefit even more patients with heart problems in China, cardiology experts said.

As the company pursues approvals for clinical trials overseas, Chen Chen, founder and CEO of CH Biomedical, which developed the pump and now manufactures it, said the device is proof of Chinese researchers' prowess in overcoming the complexity of making artificial hearts.

"Our foray into the foreign market of blood pumps is also likely to drive down costs of such devices and benefit a wider population who suffer from heart failure," Chen said.

At the core of the device is magnetic levitation technology, the same method that helps to reduce friction and significantly boosts the speed of trains.

"The technology essentially allows developers to reduce the size of the device, minimizing blood clots and bleeding, and thus improve overall efficiency and safety of the heart pump," Hu Shengshou, president of Fuwai Hospital, said at an academic conference in Beijing in November.

Global research into artificial hearts began in the 1960s, but "the fruition of many pioneers' efforts has only been seen over the last 10 years", said Wu Zhongjun, a professor of surgery at the University of Maryland's School of Medicine.

Wu said the new device, with its compact size and high compatibility with living tissue, will bring a wide range of concrete benefits to patients, including improving their quality of life, facilitating follow-up treatment and alleviating healthcare costs.

China was a latecomer to the development of artificial hearts, and some heart failure patients have died while awaiting donor hearts.

It is estimated that the number of people diagnosed with heart failure in China has climbed to 10 million in recent years, but only about 300 heart transplants are conducted annually.

"Chinese scientists did not delve deeply into this field until 2005," said Mo Ran, a surgeon at Nanjing Drum Tower Hospital in Jiangsu.

"The market potential of the device is significant for patients with severe heart failure because placing blood pumps inside their bodies is the best option to sustain their lives and maintain a good quality of life," Mo said.

He added that it is necessary to keep monitoring the health status of recipients and analyze their test results to fully validate the reliability of the device.

"Also, current trials are considered small scale," Mo said. "But the technology is certainly promising, and it's encouraging to see that China has finally caught up with global industry leaders in this area."
 
.
Cellular Biomedicine Group's ReJoin® Therapy Receives Stem Cell Drug Application Acceptance For Phase II Clinical Trials by China NMPA

CBMGcolourEN_Logo.jpg


NEWS PROVIDED BY
Cellular Biomedicine Group
Sep 27, 2019, 22:49 ET​

SHANGHAI and NEW YORK, Sept. 27, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that a drug application* for its off-the-shelf autologous adipose-derived mesenchymal progenitor cell (haMPC) ReJoin® therapy for Knee Osteoarthritis (KOA) has been accepted for a Phase II clinical trial in China.


....

https://www.prnewswire.com/news-rel...-clinical-trials-by-china-nmpa-300927246.html
 
. .
China's first self-developed carbon-ion therapy system gets market access
Source: Xinhua| 2019-10-09 16:04:03|Editor: ZX

LANZHOU, Oct. 9 (Xinhua) -- China's first self-developed carbon-ion therapy system has been approved by the national drug regulator and obtained market access.

This is the first time that the National Medical Products Administration (NMPA) has approved a domestically produced carbon-ion therapy system, according to the official website of the national drug regulator.

Installed in Wuwei Cancer Hospital in Gansu Province, the system was co-developed by the Institute of Modern Physics under the Chinese Academy of Sciences and a subsidiary company.

The product is composed of an accelerator system and a treatment system, which includes two treatment rooms that can provide carbon-ion beams for the treatment of malignant tumors.

The approval of the system marks a new step in the development of high-end medical equipment in China. It will also contribute to the development of cancer diagnosis and treatment in the country, according to the NMPA.

A report published by the National Cancer Center in 2017 showed that China has nearly 25 percent of the world's new cancer cases, with 10,000 cancer patients added per day. Every year, there are 2 million cancer-induced deaths. Lung, breast and stomach cancers are the most common types.
 
.
NEWS RELEASE 9-OCT-2019
CTFH and Insilico collaborate on accelerating first-in-class therapeutics using AI
INSILICO MEDICINE

CTFH and Insilico Collaborate On Accelerating First-in-Class Therapeutics Using AI. CREDIT: Insilico Medicine

Research Collaboration Highlights
  • The collaboration aims to accelerate drug discovery and development with an AI-enabled platform for triple-negative breast cancer;
  • CTFH is one of the top pharmaceutical companies in China focused on innovative drug discovery and development, with a strong internal R&D team and integrated R&D capabilities;
  • The project value is up to $200 million, including an upfront payment, milestone payments, and royalties based on the net product sales;
  • CTFH has achieved significant milestones in first-in-class drug development. With this partnership, CTFH will generate novel molecules with specified properties using Insilico's next-generation AI platform;
  • This partnership will speed up the R&D process, reduce the cost and ultimately benefit the patients;
HONG KONG, and NANJING, CHINA - October 9, 2019 (12PM London time) - Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program research collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. ("CTFH"), taking on previously undruggable targets. Insilico Medicine will be eligible to receive up to $200 million for the achievement of milestone payments and royalties based on the net sales on the products from the collaboration. This partnership is expected to accelerate drug discovery and development with an AI-enabled platform for triple-negative breast cancer.

CTFH is an active adopter of state-of-the-art technologies and has achieved significant milestones in first-in-class drug development. Wenyu Xia, General Manager of CTFH, said: "We are very pleased to establish the partnership with Insilico Medicine, entering the new era of AI-enabled drug development. We look forward to a long-term partnership with Insilico Medicine. As the premier AI drug discovery company in the industry, Insilico Medicine has demonstrated capabilities to generate novel molecules with specified properties using its next-generation AI platform. We believe that this collaboration will speed up the R&D process, reduce the cost and provide greater benefits to patients."

Last month, Insilico Medicine published a landmark paper in Nature Biotechnology, demonstrating the application of its generative tensorial reinforcement learning systems in the generation of novel molecules for simple kinases in 46 days, including experimental validation. It also announced a $37 million round led by prominent biotechnology and AI investors.


CTFH and Insilico collaborate on accelerating first-in-class therapeutics using AI | EurekAlert! Science News
 
.
21:13, 09-Oct-2019
Chinese announces more reimbursements for two outpatient drug types
Liu Hongcai

China has announced higher reimbursements for two types of outpatient drugs. Patients taking medicines for hypertension and diabetes will now be reimbursed more than 50 percent of the drug costs by medical insurance funds, according to the National Health Commission.

According to the commission, the drugs for the two chronic diseases are regulated by the Catalogue of Drugs for Basic National Medical Insurance. The incentive policy will benefit over 300 million patients who are covered by urban and rural residential medical insurance. Current policies will still apply to patients who have already been included in the insurance system for chronic and special diseases.

As for the medical insurance fund for urban and rural residents, Chen Jinfu, deputy administrator of the National Healthcare Security Administration, said that currently China's insurance funds have been well supplied.

"In 2018, the income of healthcare insurance for China's urban and rural residents was over 780 billion yuan, and expenditures were over 710 billion, a surplus of over 70 billion. The current healthcare insurance fund will continue to run well," said Chen.

The move is intended to help those who continuously take the drugs long term and improve the health of senior citizens, as China has over 180 million elderly citizens suffering from chronic diseases, of whom 75 percent have one type or more.
 
.
Hong Kong researchers develop world's 1st AI-enabled portable blood test instrument
Source: Xinhua| 2019-10-11 17:06:07|Editor: Li Xia

HONG KONG, Oct. 11 (Xinhua) -- The research team of the Chinese University of Hong Kong has developed the world's first "AI-enabled Portable Quantitative Phase Microscope (QPM) for Blood Testing" that provides low-cost, fast and high efficiency blood testing technology, the university announced on Thursday.

According to the researchers, traditional blood testing needs to be handled by professionals and the results can take hours or even days. The instruments involved are bulky and expensive, which cannot be moved easily to different laboratories especially in remote areas. Besides, the morphology of the cells may be affected through staining or labeling, which in turn, may affect the test results.

The novel instrument developed by the university's research team weighs less than 5 kg and is a size similar to a briefcase that can be carried everywhere. The analysis process is completed by the computer automatically in a matter of minutes, with over 90 percent accuracy.

Zhou Renjie, a professor from the department of Biomedical Engineering of the university, said that in the past, researchers have failed to combine artificial intelligence with traditional blood testing methods, because it is difficult to distinguish cell images.

"Through our high-precision QPM technology, we can effectively combine it with the deep learning technology of artificial intelligence," Zhou said, adding that the new technology can automatically distinguish different cells from healthy volunteers' blood samples.

The team has completed the proof-of-concept study and is planning to get clinical certification by working with hospitals starting in 2020, expecting the commercialization of low-cost QPM after three to five years.

In the future, the team will develop other artificial intelligence models of this portable quantitative phase microscopy technique that can be used to distinguish red blood cells and all other blood cell types, hoping to detect cancer cells in peripheral blood eventually.
 
.
China approves sale of home-grown new Alzheimer's drug
Source: Xinhua| 2019-11-03 01:19:14|Editor: Mu Xuequan

BEIJING, Nov. 2 (Xinhua) -- A home-grown drug for treating Alzheimer's disease has been approved by the National Medical Products Administration to hit the market, according to its developers Saturday.

The drug, GV-971, was developed by Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences and Green Valley Pharmaceutical Co., Ltd, after research efforts of 22 years.

A total of 1,199 persons participated in the three-phase clinical trials. The 36-week-long Phase 3 clinical study showed that the drug can improved cognition in patients with mild to moderate Alzheimer's disease, the developers said.

Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys memory, thinking ability, and the capability to carry out simple tasks. The disease affects about 48 million people worldwide, and the number is expected to increase with the aging population.
 
.
View attachment 587431
During an expedition to the Antarctic, Russian surgeon Leonid Rogozov became seriously ill. He needed an operation - and as the only doctor on the team, he realised he would have to do it himself.

As the polar winter rolled in, 27-year-old Leonid Rogozov started to feel tired, weak and nauseous. Later, a strong pain developed down the right side of his abdomen.

"Being a surgeon, he had no difficulty in diagnosing acute appendicitis," says his son, Vladislav. "It was a condition he'd operated on many times, and in the civilised world it's a routine operation. But unfortunately he didn't find himself in the civilised world - instead he was in the middle of a polar wasteland."

Rogozov was part of the sixth Soviet Antarctic expedition - a team of 12 had been sent to build a new base at the Schirmacher Oasis.

The Novolazarevskaya Station was up and running by the middle of February 1961, and with their mission complete the group settled down to see out the hostile winter months.
View attachment 587432
But by the end of April, Rogozov's life was in danger and he had no hope of outside help. The journey from Russia to the Antarctic had taken 36 days by sea, and the ship wouldn't be back for another year. Flying was impossible because of the snow and blizzards.

"He was confronted with a very difficult situation of life and death," says Vladislav. "He could wait for no help, or make an attempt to operate on himself."
It was not an easy choice. Rogozov knew his appendix could burst and if that happened, it would almost certainly kill him - and while he considered his options, his symptoms got worse.

"He had to open his own abdomen to take his intestines out," says Vladislav. "He didn't know if that was humanly possible."

In addition, this was the Cold War, with East and West competing in nuclear, space and polar races - the weight of which rested on both nations and individuals.

The commander in charge of the Novolazarevskaya base had to get Moscow's blessing for the operation to go ahead. "If my father was to fail and die it would definitely put a hard hat of negative publicity on the Soviet Antarctic programme," says Vladislav.

Rogozov made his decision - he would perform an auto-appendectomy rather than die not doing anything.

"I did not sleep at all last night. It hurts like the devil! A snow storm whipping through my soul, wailing like 100 jackals," he wrote in his diary.

"Still no obvious symptoms that perforation is imminent, but an oppressive feeling of foreboding hangs over me… This is it… I have to think through the only possible way out - to operate on myself… It's almost impossible… but I can't just fold my arms and give up."
View attachment 587437
Rogozov worked out a detailed plan for how the operation would unfold and assigned his colleagues specific roles and tasks.

He nominated two main assistants to hand him instruments, position the lamp, and hold a mirror - he planned to use the reflection to see what he was doing. The station director was also in the room, in case one of the others became faint.

"He was so systematic he even instructed them what to do if he was losing consciousness - how to inject him with adrenalin and perform artificial ventilation," says Vladislav. "I don't think his preparation could have been better."

A general anaesthetic was out of the question. He was able to administer a local anaesthetic to his abdominal wall but once he had cut through, removing the appendix would have to be done without further pain relief, in order to keep his head as clear as possible.

"My poor assistants! At the last minute I looked over at them. They stood there in their surgical whites, whiter than white themselves," Rogozov wrote later. "I was scared too. But when I picked up the needle with the novocaine and gave myself the first injection, somehow I automatically switched into operating mode, and from that point on I didn't notice anything else."
View attachment 587438
Rogozov had intended to use a mirror to help him operate but he found its inverted view too much of a hindrance so he ended up working by touch, without gloves.

As he reached the final and hardest part of the operation, he almost lost consciousness. He began to fear he would fail at the final hurdle.

"The bleeding is quite heavy, but I take my time... Opening the peritoneum, I injured the blind gut and had to sew it up," Rogozov wrote. "I grow weaker and weaker, my head starts to spin. Every four to five minutes I rest for 20 - 25 seconds.

"Finally here it is, the cursed appendage! With horror I notice the dark stain at its base. That means just a day longer and it would have burst… My heart seized up and noticeably slowed, my hands felt like rubber. Well, I thought, it's going to end badly and all that was left was removing the appendix."

But he didn't fail. After nearly two hours he had completed the operation, down to the final stitch.

Then, before allowing himself to rest, he instructed his assistants how to wash the surgical instruments and only when the room was clean and tidy did Rogozov take some antibiotics and sleeping tablets.

It was a staggering achievement. "Most importantly he was relieved because he had another chance to live," says Vladislav.

Rogozov returned to his normal duties just two weeks later.
https://www.bbc.com/news/magazine-32481442


That is due to heredity. Indeed, in today's world, everything is decided by the global world sentient A.I., known as Skynet or the Matrix.


If one's ancestor used to be wealthy, then one would expect to be rich too. Similarly, those at war with the British Empire during WWII have mostly been "gratified" with a subsequent war by the U.S., right after the establishment of the Pax Americana: Koreas, Indochina, Iraq, Persia, Libya, etc.

In this context, one should check the surgeon's genealogy.

Meanwhile, the ancient Chinese have developed surgical operation without anesthetics for centuries. With electrically conducting needles strategically inserted, as a way to shunt neural influx. Discovering the founding principle behind neuroscience, thus unlocking the 20th century mind-control (psychotronics).


Chinese Open heart surgery without anesthesia


https://www.youtube.com/watch?v=6ThmAqf--t8
1. Using Acupuncture Analgesia in Surgery. Posted Aug 26, 2009

https://www.youtube.com/watch?v=CF82SRJv-y8
2. 1970s China, Man Has Operation Using Acupuncture Anesthesia, Chinese Medicine

6e323515d66ee30841cae4a9a7318d3b72b3e685.gif

ae4ffdaeb02c2ea160fb33e41686a846f36755ca.gif

:cool::smokin:8-)
55abcc242354c9c1c73538db5d8c7b984de5ca52.gif
 
.
China's first robot-assisted cochlea implant a success
Cai Wenjun
14:00 UTC+8, 2019-11-04

Shanghai No. 9 People’s Hospital announced the success of the nation’s first robot-assisted artificial cochlea implant surgery.

The operation, which involved inserting electrode poles into the patient's cochlea, was conducted using a robotic arm instead of a doctor’s hand to improve stability and accuracy, the hospital said on Monday.

“Artificial cochlea implant surgery is the most effective treatment for patients with serious hearing disability and over 800,000 people have received such implants around the world,” said Dr Wu Hao, chief surgeon of the first robot-assisted implant operation. “The procedure requires a high degree of surgical skill, due to the small operating area and the need for accuracy. It's difficult to avoid shaking of the fingers, or an imbalance of strength, when inserting the electrode poles, which are 0.4 milliliters in diameter and 20 to 30 milliliters in length. Any shake or improper pressure can cause damage to the delicate structure inside cochlea.”

Surgical robots can help overcome problems caused by a human’s physical limitations, he said.

The hospital has established a Sino-French joint robot laboratory dedicated to otology surgery with Paris Public Hospitals Group. It will also boost domestic production of high-tech products and the transformation of clinical research into practical devices. A new generation of medical devices for otology surgery is also under development.

1a4790b2-a7da-4779-8668-35b72d114a89_0.jpg
Shanghai No. 9 People's Hospital / Ti Gong
Dr Wu Hao (first) conducts the nation's first robot-assisted artificial cochlea implant surgery.
 
.
MAY 8, 2019
Chinese researchers try brain implants to treat drug addicts
by Erika Kinetz

chineseresea.jpg
This Monday, Oct. 29, 2018 photo shows a brain scan of a methamphetamine addict with the path of electrodes that doctors at Ruijin Hospital in Shanghai, China implanted to stimulate an area of the brain associated with addiction. Western attempts to push forward with human trials of deep brain stimulation for drug addiction have foundered, even as China has emerged as a hub for this kind of research. But the vast suffering wrought by the U.S. opioid epidemic may be changing the risk-reward calculus. Now, the experimental surgery for addiction is coming to America. (AP Photo/Erika Kinetz)

Patient Number One is a thin man, with a scabby face and bouncy knees. His head, shaved in preparation for surgery, is wrapped in a clean, white cloth.

Years of drug use cost him his wife, his money and his self-respect, before landing him in this drab yellow room at a Shanghai hospital, facing the surgeon who in 72 hours will drill two small holes in his skull and feed electrodes deep into his brain.

The hope is that technology will extinguish his addiction, quite literally, with the flip of a switch.

The treatment—deep brain stimulation—has long been used for movement disorders like Parkinson's. Now, the first clinical trial of DBS for methamphetamine addiction is being conducted at Shanghai's Ruijin Hospital, along with parallel trials for opioid addicts. And this troubled man is the very first patient.

The surgery involves implanting a device that acts as a kind of pacemaker for the brain, electrically stimulating targeted areas. While Western attempts to push forward with human trials of DBS for addiction have foundered, China is emerging as a hub for this research.

Scientists in Europe have struggled to recruit patients for their DBS addiction studies, and complex ethical, social and scientific questions have made it hard to push forward with this kind of work in the United States, where the devices can cost $100,000 to implant.

China has a long, if troubled, history of brain surgery on drug addicts. Even today, China's punitive anti-drug laws can force addicts into years of compulsory treatment, including "rehabilitation" through labor. It has a large patient population, government funding and ambitious medical device companies ready to pay for DBS research.

2-chineseresea.jpg
Dr. Li Dianyou uses a tablet computer to adjust the settings of a deep brain stimulation device implanted in the brain of a methamphetamine addict named Yan, left, on Monday, Oct. 29, 2018, at Ruijin Hospital in Shanghai, China. Western attempts to push forward with human trials of DBS for drug addiction have foundered, even as China has emerged as a hub for this kind of research. But the vast suffering wrought by the U.S. opioid epidemic may be changing the risk-reward calculus. Now, the experimental surgery Yan underwent is coming to America. (AP Photo/Erika Kinetz)

There are eight registered DBS clinical trials for drug addiction being conducted in the world, according to a U.S. National Institutes of Health database. Six are in China.

But the suffering wrought by the opioid epidemic may be changing the risk-reward calculus for doctors and regulators in the United States. Now, the experimental surgery Patient Number One is about to undergo is coming to America. In February, the U.S. Food and Drug Administration greenlighted a clinical trial in West Virginia of DBS for opioid addicts.

___

HUMAN EXPERIMENTS

Patient Number One insisted that only his surname, Yan, be published; he fears losing his job if he is identified.

He said doctors told him the surgery wasn't risky. "But I still get nervous," he said. "It's my first time to go on the operating table."

Three of Yan's friends introduced him to meth in a hotel room shortly after the birth of his son in 2011. They told him: Just do it once, you've had your kid, you won't have problems.

4-chineseresea.jpg

A brain surgery patient walks down the main corridor of Ruijin Hospital's functional neurosurgery center in Shanghai, China on Monday, Oct. 29, 2018. Doctors at Ruijin are experimenting with brain surgery to treat a range of psychiatric conditions, including anorexia, Tourette syndrome and addiction. (AP Photo/Erika Kinetz)

Smoking made Yan feel faint and slightly unhinged. Later, he found meth brought crystalline focus to his mind, which he directed at one thing: Cards. Every time Yan smoked, he gambled. And every time he gambled, he lost—all told, around $150,000 since he started using drugs, he estimated.

His wife divorced him. He rarely saw his son.

Yan checked into a hospital for detox, moved to another town to get away from bad influences, took Chinese traditional medicine. But he relapsed every time. "My willpower is weak," he said.

Last year his father, who had a friend who had undergone DBS surgery at Ruijin, gave him an ultimatum: Back to rehab or brain surgery. "Of course, I chose surgery," Yan said. "With surgery, I definitely have the chance to get my life back."

Before there were brain implants in China there was brain lesioning. Desperate families of heroin addicts paid thousands of dollars for unproven and risky surgeries in which doctors destroyed small clumps of brain tissue. Brain lesioning quickly became a profit center at some hospitals, but it also left a trail of patients with mood disorders, lost memories and altered sex drives.

In 2004, China's Ministry of Health ordered a halt to brain lesioning for addiction at most hospitals. Nine years later, doctors at a military hospital in Xi'an reported that roughly half of the 1,167 addicts who had their brains lesioned stayed off drugs for at least five years.

DBS builds on that history. But unlike lesioning, which irreversibly kills brain cells, the devices allow brain interventions that are—in theory—reversible. The technology has opened a fresh field of human experimentation globally.

3-chineseresea.jpg

Bloodied white mesh covers the head of a methamphetamine addict named Yan on Monday, Oct. 29, 2018, three days after he had a deep brain stimulation device implanted as part of a clinical trial at Ruijin Hospital in Shanghai, China. The hope is that DBS will extinguish his addiction, quite literally, with the flip of a switch. Critics say such human experiments are premature and risky, but U.S. regulators in February greenlighted a human trial of DBS for opioid addiction at West Virginia University. (AP Photo/Erika Kinetz)

"As doctors we always need to think about the patients," said Dr. Sun Bomin, director of Ruijin Hospital's functional neurosurgery department. "They are human beings. You cannot say, 'Oh, we do not have any help, any treatment for you guys.'"

Sun said he has served as a consultant for two Chinese companies that make deep brain stimulators—SceneRay Corp. and Beijing PINS Medical Co. He has tried to turn Ruijin into a center of DBS research, not just for addiction, but also Tourette syndrome, depression and anorexia.

In China, DBS devices can cost less than $25,000. Many patients pay cash.

"You can rest assured for the safety of this operation," Yan's surgeon, Dr. Li Dianyou, told him. "It is no problem. When it comes to effectiveness, you are not the first one, nor the last one. You can take it easy because we have done this a lot."

In fact, there are risks. There is a small chance Yan could die of a brain hemorrhage. He could emerge with changes to his personality, seizures, or an infection. And in the end, he may go right back on drugs.

____

5-chineseresea.jpg

Doctors discuss a plan on how to implant a deep brain stimulation device in the brain of a methamphetamine addict named Yan on Friday, Oct. 26, 2018. Western attempts to push forward with human trials of DBS for drug addiction have foundered, even as China has emerged as a hub for this kind of research. But the vast suffering wrought by the U.S. opioid epidemic may be changing the risk-reward calculus. Now, the experimental surgery Yan underwent is coming to America. (AP Photo/Erika Kinetz)

A BUZZING DRILL

Some critics believe this surgery should not be allowed.

They argue that such human experiments are premature, and will not address the complex biological, social and psychological factors that drive addiction. Scientists don't fully understand how DBS works and there is still debate about where electrodes should be placed to treat addiction. There is also skepticism in the global scientific community about the general quality and ethical rigor—particularly around issues like informed consent—of clinical trials done in China.

"It would be fantastic if there were something where we could flip a switch, but it's probably fanciful at this stage," said Adrian Carter, who heads the neuroscience and society group at Monash University in Melbourne. "There's a lot of risks that go with promoting that idea."

The failure of two large-scale, U.S. clinical trials on DBS for depression around five years ago prompted soul-searching about what threshold of scientific understanding must be met in order to design effective, ethical experiments.

"We've had a reset in the field," said Dr. Nader Pouratian, a neurosurgeon at UCLA who is investigating the use of DBS for chronic pain. He said it's "a perfectly appropriate time" to research DBS for drug addiction, but only "if we can move forward in ethical, well-informed, well-designed studies."

In China, meanwhile, scientists are charging ahead.

At 9 a.m. on a grey October Friday in Shanghai, Dr. Li drilled through Yan's skull and threaded two electrodes down to his nucleus accumbens, a small structure near the base of the forebrain that has been implicated in addiction.

1-chineseresea.jpg

People walk past an entrance to Ruijin Hospital on Thursday, Oct. 25, 2018, in Shanghai, China. Doctors at Ruijin have tried to turn the hospital into a center of deep brain stimulation research. The hope is that the technology will heal a host of conditions, including addiction, with the flip of a switch. Western attempts to push forward with human trials of DBS for addiction have foundered, even as China emerged as a hub for this kind of research. (AP Photo/Erika Kinetz)

Yan was awake during the surgery. The buzzing of the drill made him tremble.

At 4 p.m. the same day, Yan went under general anesthesia for a second surgery to implant a battery pack in his chest to power the electrodes in his skull.

Three hours later, Yan still hadn't woken from the anesthesia. His father began weeping. His doctors wondered if drug abuse had somehow altered his sensitivity to anesthesia.

Finally, after 10 hours, Yan opened his eyes.

___

BODY COUNT

According to the U.S. Centers for Disease Control and Prevention, more than 500,000 Americans died of drug overdoses in the decade ending in 2017—increasingly, from synthetic opioids that come mainly from China, U.S. officials say. That's more than the number of U.S. soldiers who died in World War II and Vietnam combined.

6-chineseresea.jpg

A nurse walks through the functional neurosurgery center at Shanghai's Ruijin Hospital on Monday, Oct. 29, 2018. Doctors at Ruijin are experimenting with brain surgery to treat a range of psychiatric conditions, including anorexia, Tourette syndrome and addiction. Six of the eight human trials of deep brain stimulation for addiction underway globally are being done in China, according to a U.S. government database. (AP Photo/Erika Kinetz)

The body count has added urgency to efforts to find new, more effective treatments for addiction. While doctors in the U.S. are interested in using DBS for addiction, work funded by the U.S. National Institutes of Health is still focused on experiments in animals, not people.

At least two U.S. laboratories dropped clinical trials of DBS for treating alcoholism over concerns about study design and preliminary results that didn't seem to justify the risks, investigators who led the studies told The Associated Press.

"The lack of scientific clarity, the important but strict regulatory regime, along with the high cost and risk of surgery make clinical trials of DBS for addiction in the U.S. difficult at the present time," said Dr. Emad Eskandar, the chairman of neurological surgery at Albert Einstein College of Medicine in New York.

China's studies have offered mixed results. Sun and his colleagues have published one case study, describing a heroin addict who fatally overdosed three months after getting DBS. But a separate pilot study published in January by doctors at a military hospital in Xi'an showed that five of eight heroin addicts stayed off drugs for two years after DBS surgery.

Based on those results, SceneRay is seeking Chinese regulatory approval of its DBS device for addiction, and funding a multi-site clinical trial targeting 60 heroin addicts. SceneRay chairman Ning Yihua said his application for a clinical trial in the U.S. was blocked by the U.S. Food and Drug Administration.

But in February, the FDA greenlighted a separate, pilot trial of DBS for four opioid addicts, said Dr. Ali Rezai, who is leading the study at the West Virginia University Rockefeller Neuroscience Institute. They hope to launch the trial in June, with funding from the National Institute on Drug Abuse.

The FDA declined comment.

7-chineseresea.jpg

Orderlies roll a brain surgery patient out of the functional neurosurgery center at Ruijin Hospital in Shanghai, China on Monday, Oct. 29, 2018. Doctors at Ruijin are experimenting with deep brain stimulation as a treatment for addiction. The hope is that the technology will extinguish addiction, quite literally, with the flip of a switch. Critics say such experiments are premature and risky, but U.S. regulators in February greenlighted a human trial of DBS for opioid addiction at West Virginia University. (AP Photo/Erika Kinetz)

"People are dying," Rezai said. "Their lives are devastated. It's a brain issue. We need to explore all options."

___

'YOU CAME TOO LATE'

Two unsteady days after Yan's surgery, doctors switched on his DBS device. As the electrodes activated, he felt a surge of excitement. The current running through his body kept him awake; he said he spent the whole night thinking about drugs.

The next day, he sat across from Dr. Li, who used a tablet computer to remotely adjust the machine thrumming inside Yan's head.

"Cheerful?" Li asked as the touched the controls on the tablet.

"Yes," Yan answered.

8-chineseresea.jpg

A stereotactic device presses into the head of a brain surgery patient at Ruijin Hospital's functional neurosurgery center in Shanghai, China on Monday, Oct. 29, 2018. Doctors at Ruijin are experimenting with deep brain stimulation as a treatment for addiction. The hope is that the technology will extinguish addiction, quite literally, with the flip of a switch. Critics say such experiments are premature and risky, but U.S. regulators in February greenlighted a human trial of DBS for opioid addiction at West Virginia University. (AP Photo/Erika Kinetz)

Li changed the settings. "Now?"

"Agitated," Yan said. He felt heat in his chest, then a beating sensation, numbness and fatigue. Yan began to sweat.

Li made a few more modifications. "Any feelings now?"

"Pretty happy now," Yan said.

He was in high spirits. "This machine is pretty magical. He adjusts it to make you happy and you're happy, to make you nervous and you're nervous," Yan said. "It controls your happiness, anger, grief and joy."

Yan left the hospital the next morning.

More than six months later, he said he's still off drugs. With sobriety, his skin cleared and he put on 20 pounds. When his friends got back in touch, he refused their drugs. He tried to rekindle his relationship with his ex-wife, but she was pregnant with her new husband's child.

9-chineseresea.jpg

A man leaves the Center for Functional Neurosurgery at Ruijin Hospital in Shanghai, China on Monday, Oct. 29, 2018. Doctors at Ruijin have tried to turn the hospital into a center of deep brain stimulation research. (AP Photo/Erika Kinetz)

"The only shame is that you came too late," she told him.

Sometimes, in his new life, he touches the hard cable in his neck that leads from the battery pack to the electrodes in his brain. And he wonders: What is the machine is doing inside his head?

Explore further

© 2019 The Associated Press. All rights reserved.


Chinese researchers try brain implants to treat drug addicts | MedicalXpress
Deep brain stimulation is being tested to treat opioid addiction - The Washington Post
 
.
07:58, 15-Nov-2019
FDA approves drug made by China's BeiGene to treat rare form of lymphoma
Updated 10:16, 15-Nov-2019
CGTN

The U.S. Food and Drug Administration (FDA) Thursday approved BeiGene Ltd's drug to treat a rare form of blood cancer, validating China-based drugmaker's strategy of largely using data from trials held outside the U.S. to file for approval.

The company tested the treatment, Brukinsa, in 118 patients with mantle cell lymphoma (MCL) enrolled in two studies. About three-quarters of the patients were Asian and 21 percent Caucasian, while 10-15 percent were from the United States, BeiGene said.

The FDA granted accelerated approval to the capsules for treatment of MCL in adults who have received at least one prior therapy.

MCL is a rare, aggressive form of non-Hodgkin lymphoma, a blood cancer that most often affects men aged over 60 years. The company estimates between 3,000 and 4,000 new patients were diagnosed in the U.S. in 2015.

BeiGene's new treatment will compete with Johnson & Johnson and AbbVie Inc's Imbruvica and AstraZeneca's Calquence, as well as Celgene's Revlimid.

The company did not disclose the price of Brukinsa, saying it would be set once the treatment is commercially available in the coming weeks.

"The FDA has assessed our data and they believe that the response rates are applicable to all ethnic groups, and is representative of a population that would be treated in the U.S.," Jane Huang, chief medical officer for hematology at BeiGene told Reuters ahead of the decision.

"We are now incorporating China patients into global clinical trials in a greater proportion, and this is a strategy for us to be able to get our drugs to people around the world as quickly as possible."

By avoiding large U.S. trials, drugmakers are more likely to quickly enroll patients in their studies, particularly for rare diseases like MCL where companies must compete with rivals testing their novel drugs in the same group of patients.

"The FDA has made public statements ... that they are interested in expediting approvals on drugs for oncology from China," Cowen analyst Yaron Werber said.

"This is the first time that the FDA ... approved a drug based on efficacy data that is predominantly from China."

Source(s): Reuters
 
.
More accurate surgical treatment of lung cancer promoted nationwide
Source: Xinhua| 2019-11-19 16:02:37|Editor: ZX

BEIJING, Nov. 19 (Xinhua) -- Chinese hospitals are adopting a new surgical technique for early-stage lung cancer treatment and have issued a training video for doctors.

Using a technique called "anatomic pulmonary segmentectomy," surgeons do not have to remove the whole lung lobe for treating nodules, but only the lung segment where the nodules are located, which is a radical change in both techniques and postoperative effect, said Liu Yang, director of the thoracic surgery department at the General Hospital of the People's Liberation Army (PLAGH).

The lungs are made up of lobes, with two on the left and three on the right. Each lung lobe is divided into small branches called lung segments.

The technique uses 3D computed tomography, which allows doctors to conduct more precise surgeries under a thoracoscope and thus preserve more healthy lung tissue, Liu said.

Some leading hospitals have regularly performed the surgeries, but the technique's complexity has prevented it from becoming mainstream nationwide.

Liu and his colleagues shot a training video and the Chinese Medical Doctor Association and the PLAGH have organized several training programs for about 1,000 doctors nationwide.
 
.
China's Microread Opens Central Asia's First DNA Testing Lab With Kazakhstani Uni
LIAO SHUMIN
DATE : DEC 05 2019/SOURCE : YICAI

top.jpg

China's Microread Opens Central Asia's First DNA Testing Lab With Kazakhstani Uni

(Yicai Global) Dec. 5 -- A unit of China's Microread Genetics and Nazarbayev University have kicked off Central Asia's first genetic testing lab on the Kazakhstani institution's campus one and a half years after agreeing on the project.

The lab, located on the premises of the School of Science and Technology, can carry out more 40 types of tests related to the fields of precision medicine, agriculture, and forensics, Xinhua News Agency reported. The facility is expected to conduct 30,000 tests each year.

In June 2018, Microread and Nazarbayev University signed a memorandum of cooperation on establishing the lab.

Founded in 2007, Beijing-based Microread makes in vitro diagnostic reagents to detect changes in DNA that can help screen for cancer, cardiovascular diseases, or birth defects.
 
.

Latest posts

Back
Top Bottom